KEEPING YOU UP TO DATEClearstate Healthcare InsightsClearstate Insights is your single source to all our latest healthcare intelligence. From recently published reports offering thought-provoking analysis, to information about new products and services, we will ensure you are always kept informed. Sign up to Clearstate’s newsletter
Outside of covid-19 diagnostics: Nine out of 16 APAC IVD markets have recovered to pre-pandemic levels Asia-Pacific (APAC) IVD markets have grown and exceeded… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Asia | Centralised Diagnostics (CEDx) | Covid-19 testing | Infectious Diseases Testing Monitor | IVD Gateway | Molecular Diagnostics (MDx)
Most common cancer biomarkers for Europe NGS testing: RAS, BRAF, EGFR Most-commonly tested cancer biomarkers using NGS in Europe… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Larger gene panels are the predominant NGS testing strategy in EU5 Larger gene panels are the predominant NGS testing strategy… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Europe: precision medicine and access to NGS cancer biomarker testing Precision medicine and access to NGS cancer biomarker… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Watch on-demand: Will Covid-19 Accelerate the Next Wave of Adoption of Next-Generation Sequencing (NGS) in Healthcare? Now, sequencing looks set to become even more integral in… Covid-19 testing | In-vitro diagnostics | Next Generation Sequencing (NGS) | Uncategorised | Global | IVD Gateway | Next Generation Sequencing (NGS)
The fastest-growing areas for LATAM’s next-generation sequencing market The next-generation sequencing (NGS) market is expected to… In-vitro diagnostics | Next Generation Sequencing (NGS) | Americas | IVD Gateway | Next Generation Sequencing (NGS)
The fastest-growing areas for APAC’s next-generation sequencing market The next-generation sequencing (NGS) market is expected to… In-vitro diagnostics | Next Generation Sequencing (NGS) | Asia | IVD Gateway | Next Generation Sequencing (NGS)
2022 healthcare megatrends shaping IVD 2022 healthcare megatrends shaping IVD… In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Point-of-care testing (POCT) | Asia | Europe | Middle East & Africa | IVD Gateway | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Point-of-care testing (POCT)
Keeping ahead of infectious diseases in Asia-Pacific with increased testing Our new briefing paper looks at the testing trends in… Covid-19 testing | In-vitro diagnostics | Infectious Diseases Testing Monitor | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Asia | IVD Gateway | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Point-of-care testing (POCT)
[On-demand Webinar] Will Covid-19 Accelerate the Next Wave of Adoption of Next-Generation Sequencing (NGS) in Healthcare? EIU Healthcare hosted the “Will Covid-19 Accelerate the… Covid-19 testing | In-vitro diagnostics | Next Generation Sequencing (NGS) | Asia | IVD Gateway
Sign up to our free newsletterThe latest trends and insights into the IVD and Surgical sectors, from our specialists and analysts, delivered directly to your inbox. Sign up to Clearstate’s newsletter today. Sign up now